| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/19/2013 | EP2604600A1 Isatin derivatives and their use in therapy |
| 06/19/2013 | EP2604599A1 TRPV1 antagonists and uses thereof |
| 06/19/2013 | EP2604598A1 TRPV1 antagonists and uses thereof |
| 06/19/2013 | EP2604597A1 Heterocyclic compound and use thereof |
| 06/19/2013 | EP2604596A1 Polymorphs of imatinib |
| 06/19/2013 | EP2604595A1 Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity |
| 06/19/2013 | EP2604594A1 1,2,4-Triazole derivatives as ghrelin analogue ligands of GHS receptors |
| 06/19/2013 | EP2604593A1 Polymorph of Rilpivirine hydrochloride and its use as antiviral |
| 06/19/2013 | EP2604591A1 Process for preparing aminoadamantyl carbamate derivatives |
| 06/19/2013 | EP2604282A1 Method for preparing of monodisperse oligo ethylene glycol |
| 06/19/2013 | EP2604275A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/19/2013 | EP2604274A1 Rhus verniciflua stokes extract having increased content of active flavonoid compound and method for preparing same |
| 06/19/2013 | EP2604270A1 Dextrin for suppressing elevation of blood alcohol concentration |
| 06/19/2013 | EP2604269A1 1,4-benzodiazepine-2,5-diones with therapeutic properties |
| 06/19/2013 | EP2604268A1 Process for the preparation of thiazole derivatives |
| 06/19/2013 | EP2604267A1 Process for the preparation of thiazole derivatives |
| 06/19/2013 | EP2604266A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/19/2013 | EP2604265A1 P2x7 antagonists as frontline or adjunctive treatment against status epilepticus |
| 06/19/2013 | EP2604264A1 Pharmaceutical composition for treating viral diseases |
| 06/19/2013 | EP2604263A1 Medicinal agent for prevention and/or treatment of hepatocellular carcinoma |
| 06/19/2013 | EP2604262A1 Composition comprising a reduced isoalpha acid, a mineral and a vitamin for use in the treatment of autoimmune diseases |
| 06/19/2013 | EP2604261A2 SCCA-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient |
| 06/19/2013 | EP2604260A1 Novel heterocyclic derivatives and pharmaceutical composition containing same |
| 06/19/2013 | EP2604259A1 LSD-1 enzyme inhibitors for inducing osteogenic differentiation |
| 06/19/2013 | EP2604258A1 Pharmaceutical composition comprising Losartan for treating or preventing statin based drug-induced muscle toxicity |
| 06/19/2013 | EP2604257A1 Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms |
| 06/19/2013 | EP2604256A1 Multi layer coatings |
| 06/19/2013 | EP2604254A1 Slimming composition |
| 06/19/2013 | EP2603588A1 Injectable pharmaceutical composition for preventing, stabilising and/or inhibiting pathological neovascularization-related conditions |
| 06/19/2013 | EP2603587A1 Methods and pharmaceutical compositions for the treatment of hiv-1 infections |
| 06/19/2013 | EP2603514A1 Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| 06/19/2013 | EP2603513A1 Heterocyclic compound and use thereof |
| 06/19/2013 | EP2603512A1 Derivatives of 6, 7-dihydro-3h-oxazolo [3, 4-a]pyrazine-5, 8- dione |
| 06/19/2013 | EP2603511A1 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d]pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| 06/19/2013 | EP2603510A1 New azacyclic compounds |
| 06/19/2013 | EP2603509A1 Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| 06/19/2013 | EP2603504A1 Hepatitis c virus inhibitors |
| 06/19/2013 | EP2603503A1 Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof |
| 06/19/2013 | EP2603502A1 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
| 06/19/2013 | EP2603501A1 Heterocyclic antiviral compounds |
| 06/19/2013 | EP2603497A1 A novel process for preparation of bosentan |
| 06/19/2013 | EP2603496A1 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| 06/19/2013 | EP2603495A1 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| 06/19/2013 | EP2603493A1 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 06/19/2013 | EP2603492A1 Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof |
| 06/19/2013 | EP2603490A1 Novel trpv3 modulators |
| 06/19/2013 | EP2603487A1 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 06/19/2013 | EP2603486A1 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases |
| 06/19/2013 | EP2603481A2 Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 06/19/2013 | EP2603288A1 Pharmaceutical granulate comprising imatinib mesylate |
| 06/19/2013 | EP2603239A2 Neuropilin as a biomarker for bevacizumab combination therapies |
| 06/19/2013 | EP2603224A1 Methods and compositions for preventing a condition |
| 06/19/2013 | EP2603223A1 Recombinant tumor vaccine and method of producing such vaccine |
| 06/19/2013 | EP2603222A1 Combinatory cancer treatment |
| 06/19/2013 | EP2603221A2 Ggf2 and methods of use |
| 06/19/2013 | EP2603220A1 Antisense antiviral compounds and methods for treating a filovirus infection |
| 06/19/2013 | EP2603219A1 Combination of glyt1 compound with antipsychotics |
| 06/19/2013 | EP2603218A1 Quinolyl amines as kinase inhibitors |
| 06/19/2013 | EP2603217A1 Novel 6,7-disubstituted-isoquinoline derivatives and their use |
| 06/19/2013 | EP2603216A1 Heteroaryls and uses thereof |
| 06/19/2013 | EP2603215A2 Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
| 06/19/2013 | EP2603214A1 Heteroaryls and uses thereof |
| 06/19/2013 | EP2603213A2 Methods of treating obstructive lung diseases using bitter tastants |
| 06/19/2013 | EP2603212A1 Use of rasagiline for the treatment of olfactory dysfunction |
| 06/19/2013 | EP2603211A1 Composition for treating hyperlipidemia |
| 06/19/2013 | EP2603210A1 Treatment |
| 06/19/2013 | EP2603207A2 Oral controlled release pharmaceutical compositions of blonanserin |
| 06/19/2013 | EP2603206A2 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| 06/19/2013 | EP2603205A2 Use of binders for manufacturing storage stable formulations |
| 06/19/2013 | EP2603203A2 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| 06/19/2013 | EP2603198A2 Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds |
| 06/19/2013 | EP2603097A1 Product for the upper gastric sphere |
| 06/19/2013 | EP2603096A1 Method for treating fatty liver diseases, in particular non-alcoholic steatohepatitis. |
| 06/19/2013 | EP2603090A1 Lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| 06/19/2013 | EP2603082A1 Methods for extending progression-free survival using 10-propargyl-10-deazaaminopterin |
| 06/19/2013 | EP2603080A1 Hepatitis c virus inhibitors |
| 06/19/2013 | EP2603079A1 Positive allosteric modulators of mglur2 |
| 06/19/2013 | EP2603078A1 Combination |
| 06/19/2013 | EP2603077A1 Herbal topical formulation |
| 06/19/2013 | CN203001479U Cetirizine hydrochloride tablet |
| 06/19/2013 | CN1950343B Basic amine compound and use thereof |
| 06/19/2013 | CN1845728B Pharmaceutical compositions and method of using levodopa and carbidopa |
| 06/19/2013 | CN103168042A 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| 06/19/2013 | CN103168041A 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof |
| 06/19/2013 | CN103168040A Process for manufacturing dihydropteridinones and intermediates thereof |
| 06/19/2013 | CN103168039A Imidazopyridines syk inhibitors |
| 06/19/2013 | CN103168038A Carbonate derivatives for the treatment of cough |
| 06/19/2013 | CN103168037A Synthesis and use of kinase inhibitors |
| 06/19/2013 | CN103168036A Soft cationic mitochondrial uncouplers |
| 06/19/2013 | CN103168033A Quinazoline compounds as sodium channel blockers |
| 06/19/2013 | CN103168031A Tetrahydroquinoline derivatives used as AMPK activators |
| 06/19/2013 | CN103168029A Salts and polymorphs of sulfamide ns3 inhibitors |
| 06/19/2013 | CN103168028A Cyclic amide derivative |
| 06/19/2013 | CN103167894A Inhibition of microbial growth by aconitase inhibition |
| 06/19/2013 | CN103167877A Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof |
| 06/19/2013 | CN103167875A Ep2 or ep4 agonists for treating corneal haze |
| 06/19/2013 | CN103167874A Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome |
| 06/19/2013 | CN103167873A Dosing regimes for the treatment of ocular vascular disease |
| 06/19/2013 | CN103167872A Process for the production of l-carnitine tartrate |
| 06/19/2013 | CN103167871A Compositions comprising acidic extracts of mastic gum |